JP6882180B2 - 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 - Google Patents

神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 Download PDF

Info

Publication number
JP6882180B2
JP6882180B2 JP2017543308A JP2017543308A JP6882180B2 JP 6882180 B2 JP6882180 B2 JP 6882180B2 JP 2017543308 A JP2017543308 A JP 2017543308A JP 2017543308 A JP2017543308 A JP 2017543308A JP 6882180 B2 JP6882180 B2 JP 6882180B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
ketamine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017543308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501299A (ja
JP2018501299A5 (enExample
Inventor
アレックス ニヴォロジキン，
アレックス ニヴォロジキン，
ネルソン ランドロー，
ネルソン ランドロー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorsa Therapeutics Inc
Original Assignee
Amorsa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorsa Therapeutics Inc filed Critical Amorsa Therapeutics Inc
Publication of JP2018501299A publication Critical patent/JP2018501299A/ja
Publication of JP2018501299A5 publication Critical patent/JP2018501299A5/ja
Priority to JP2021078368A priority Critical patent/JP2021120389A/ja
Application granted granted Critical
Publication of JP6882180B2 publication Critical patent/JP6882180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017543308A 2014-11-04 2015-11-04 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 Active JP6882180B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078368A JP2021120389A (ja) 2014-11-04 2021-05-06 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074645P 2014-11-04 2014-11-04
US62/074,645 2014-11-04
PCT/US2015/059113 WO2016073653A1 (en) 2014-11-04 2015-11-04 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078368A Division JP2021120389A (ja) 2014-11-04 2021-05-06 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法

Publications (3)

Publication Number Publication Date
JP2018501299A JP2018501299A (ja) 2018-01-18
JP2018501299A5 JP2018501299A5 (enExample) 2018-12-13
JP6882180B2 true JP6882180B2 (ja) 2021-06-02

Family

ID=55909773

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017543308A Active JP6882180B2 (ja) 2014-11-04 2015-11-04 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法
JP2021078368A Pending JP2021120389A (ja) 2014-11-04 2021-05-06 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078368A Pending JP2021120389A (ja) 2014-11-04 2021-05-06 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法

Country Status (18)

Country Link
US (5) US10252982B2 (enExample)
EP (2) EP4393487A3 (enExample)
JP (2) JP6882180B2 (enExample)
KR (1) KR102604397B1 (enExample)
CN (2) CN115521217A (enExample)
AU (1) AU2015343083B2 (enExample)
CA (1) CA2966737A1 (enExample)
DK (1) DK3215147T3 (enExample)
ES (1) ES2977383T3 (enExample)
FI (1) FI3215147T3 (enExample)
HU (1) HUE066468T2 (enExample)
LT (1) LT3215147T (enExample)
PL (1) PL3215147T3 (enExample)
PT (1) PT3215147T (enExample)
RS (1) RS65411B1 (enExample)
RU (1) RU2771275C2 (enExample)
SI (1) SI3215147T1 (enExample)
WO (1) WO2016073653A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
HUE051264T2 (hu) 2014-04-17 2021-03-01 Develco Pharma Schweiz Ag Ketamin orális dózisformája
WO2016073653A1 (en) 2014-11-04 2016-05-12 Amorsa Therapeutics, Inc. Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
WO2016186968A1 (en) * 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
JP6845162B2 (ja) 2015-06-27 2021-03-17 シェノックス・ファーマシューティカルズ・エルエルシー ケタミン経皮送達システム
WO2017180589A1 (en) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
CN110035997A (zh) * 2016-09-16 2019-07-19 生物制药沃克斯有限公司 羟基去甲氯胺酮前药
JPWO2018079693A1 (ja) * 2016-10-27 2019-10-31 国立大学法人千葉大学 （ｓ）−ノルケタミンおよびその塩の医薬品としての応用
CA3059775A1 (en) 2017-04-13 2018-10-18 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
WO2019025792A1 (en) 2017-07-31 2019-02-07 Small Pharma Ltd CRYSTALLINE FORMS OF HYDROXYNORKETAMINE
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2019073408A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
HUE058320T2 (hu) 2017-12-29 2022-07-28 Celon Pharma Sa Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
MX2020011653A (es) 2018-05-04 2021-02-09 Perception Neuroscience Inc Métodos de tratamiento para el abuso de sustancias.
JP2021529732A (ja) 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
EP3863617A1 (en) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
AU2020247549B2 (en) * 2019-03-25 2024-08-29 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN120817937A (zh) * 2019-08-06 2025-10-21 加利福尼亚大学董事会 聚酮化合物及其制备方法和中间体
JP7670700B2 (ja) 2019-10-11 2025-04-30 パイク セラピューティクス インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
WO2021137148A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114524737B (zh) * 2020-11-23 2024-10-22 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
EP4329737A1 (en) * 2021-04-30 2024-03-06 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
CN116730853A (zh) * 2022-03-04 2023-09-12 上海致根医药科技有限公司 新型氨基酮类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
JP2006510618A (ja) * 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
WO2008134525A1 (en) * 2007-04-26 2008-11-06 Auspex Pharmaeuticals, Inc. Deuterium labelled ketamine
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
EP3035918B1 (en) 2013-08-26 2021-06-30 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2016073653A1 (en) 2014-11-04 2016-05-12 Amorsa Therapeutics, Inc. Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Also Published As

Publication number Publication date
WO2016073653A1 (en) 2016-05-12
US20220402863A1 (en) 2022-12-22
KR20170083575A (ko) 2017-07-18
SI3215147T1 (sl) 2024-05-31
LT3215147T (lt) 2024-04-25
CN115521217A (zh) 2022-12-27
EP3215147A4 (en) 2018-05-30
AU2015343083B2 (en) 2020-07-23
RU2017119222A3 (enExample) 2019-06-07
US10981859B2 (en) 2021-04-20
HUE066468T2 (hu) 2024-08-28
US20190263749A1 (en) 2019-08-29
EP3215147B1 (en) 2024-02-28
PT3215147T (pt) 2024-04-18
RS65411B1 (sr) 2024-05-31
RU2771275C2 (ru) 2022-04-29
US20170355663A1 (en) 2017-12-14
JP2018501299A (ja) 2018-01-18
CN107106529A (zh) 2017-08-29
ES2977383T3 (es) 2024-08-22
RU2017119222A (ru) 2018-12-06
EP3215147A1 (en) 2017-09-13
US12466783B2 (en) 2025-11-11
DK3215147T3 (da) 2024-04-02
US11603348B2 (en) 2023-03-14
FI3215147T3 (fi) 2024-04-18
CA2966737A1 (en) 2016-05-12
US11613515B2 (en) 2023-03-28
US20230192593A1 (en) 2023-06-22
EP4393487A3 (en) 2024-08-21
US10252982B2 (en) 2019-04-09
PL3215147T3 (pl) 2024-06-24
JP2021120389A (ja) 2021-08-19
US20220106258A1 (en) 2022-04-07
AU2015343083A1 (en) 2017-06-08
KR102604397B1 (ko) 2023-11-21
EP4393487A2 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
JP6882180B2 (ja) 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法
US10653629B2 (en) Single layer oral dose of neuro-attenuating ketamine
CZ20022857A3 (cs) Farmaceutický prostředek
KR20240009433A (ko) 실로시빈의 제형
TW202017568A (zh) 環絲胺酸化合物的製劑及其應用
US20240360091A1 (en) Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph
US20120237563A1 (en) Controlled-release formulations of anabaseine compounds and uses thereof
TW202015684A (zh) 那曲酮、納美芬及其衍生物之前藥
US20190225573A1 (en) Vinylogous phenethylamines as neurotransmitter releasers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210506

R150 Certificate of patent or registration of utility model

Ref document number: 6882180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250